Appili Therapeutics Inc
🇨🇦XTSE.APLICanadaHealthcare
PriceCA$0.010.00 (0%)
Latest anomalies
Neutral 4 detected in the last 120 days
- High: 0
- Medium: 8
- Low: 0
Daily return: an extreme move up, far outside its trailing 60-day range
12-1M momentum: flipped sign, from positive to negative
Overnight gap: a gap up from the prior close
Realized volatility: a breakout above its trailing average
Current ratio: below the level we flag as a liquidity warning
Free with a Finzer account.
Profile
- Healthcare
- Biotechnology
- Canada
Identity
- Exchange
- Toronto Stock Exchange . XTSE
- Type
- Stock
- ISIN
- CA03783R1073
- CUSIP
- 03783R107
Company
- Employees
- 7
- Headquarters
- Halifax, Canada
Market
- Shares outstanding
- 121.3M
- Market cap
- CA$1.21M
Highlights
No high and low reported for today's session.
- Market cap
- CA$1.21M
- EPS LTM
- -CA$0.02calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- -0.53calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- 0%calculatedCalculated by Finzer, not reported by the data provider.
Fundamentals (LTM)
- Revenue
- CA$100.44K-87.86%down year on year
- Net income
- -CA$2.29M+40.03%up year on year
- Gross margin
- 100%+1.65%up year on year
- Free cash flow
- CA$992.18K+263.05%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Appili Therapeutics Inc is a company in the healthcare sector, listed on Toronto Stock Exchange (Canada) under the ticker APLI. Its market capitalisation is CA$1.21M, from 121.3M shares outstanding, as of . Across the 248 trading sessions to the shares traded between CA$0.01 and CA$0.04, and the last close of CA$0.01 sits 0% of the way up that range. The company is headquartered in Halifax, Canada, and employs about 7 people.
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.